- NCIt
- C7147
Loading cancer entity…
Loading cancer entity…
Clinical trials
9 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07010224 | Elastofibroma Dorsi: Clinical Features, Surgical Outcomes, and Risk Factors | completed | — | 102 | Ondokuz Mayıs UniversityOTHER | 0 | Jul 24, 2026 | clinicaltrials |
| NCT01526356 | Topical Rapamycin to Erase Angiofibromas in TSC(Treatment) | completed | Phase 2 | 179 | The University of Texas Health Science Center, HoustonOTHER | 2 | Oct 26, 2020 | clinicaltrials |
| NCT02634931 | Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex | completed | Phase 3 | 94 | NobelpharmaINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02635789 |
Data updated 23 days agoSource updated Jul 24, 2026source: clinicaltrials
| completed |
| Phase 3 |
| 62 |
| NobelpharmaINDUSTRY |
| 1 |
| Feb 2, 2017 |
| clinicaltrials |
| NCT01031901 | Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) | completed | Phase 1 | 52 | The University of Texas Health Science Center, HoustonOTHER | 1 | Feb 27, 2012 | clinicaltrials |